Emerging therapies for portal hypertension in cirrhosis.

about

How to Face Chronic Liver Disease: The Sinusoidal Perspective.Advances and challenges in cirrhosis and portal hypertension.Pharmacologic prevention of variceal bleeding and rebleeding.

P2860

Q38940706-A027978D-0816-4E9F-9E96-437C56DBB738 Q47095006-A9E8D691-DDB5-4E61-973D-293BF29AA946 Q50054841-1AD3CD68-164E-4FC3-9FC1-125FAB18A985

P2860

Emerging therapies for portal hypertension in cirrhosis.

Item

http://www.wikidata.org/entity/Q38826464

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Emerging therapies for portal hypertension in cirrhosis.

@en

type

Item

label

Emerging therapies for portal hypertension in cirrhosis.

@en

prefLabel

Emerging therapies for portal hypertension in cirrhosis.

@en

P1476

Emerging therapies for portal hypertension in cirrhosis.

@en

P2093

Annalisa Berzigotti

http://www.w3.org/2001/XMLSchema#string

Harikumar Nair

http://www.w3.org/2001/XMLSchema#string

Jaime Bosch

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis

Rifaximin treatment in hepatic encephalopathy

Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers

Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase

Current status of novel antifibrotic therapies in patients with chronic liver disease

Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease.

The burden of liver disease in Europe: a review of available epidemiological data.

Early administration of vapreotide for variceal bleeding in patients with cirrhosis.

Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension.

Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review.

P304

167-181

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/14728214.2016.1184647

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27148904

http://www.w3.org/2001/XMLSchema#string

Emerging therapies for portal hypertension in cirrhosis.

about

P2860

P2860

Emerging therapies for portal hypertension in cirrhosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698